Tissue factor/its pathway inhibitor system and kynurenines in chronic kidney disease patients on conservative treatment

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 7, 2009, Pages 590-594

  Pawlak, Krystyna ^a   Tankiewicz, Janina ^a   Mysliwiec, Michal ^b   Pawlak, Dariusz ^a,c  

^a Department of Monitored Pharmacotherapy ^*

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^c UNIVERSITY OF WARMIA AND MAZURY IN OLSZTYN   (Poland)

Author keywords

3 hydroxykynurenine; Chronic kidney disease; Kynurenine; Tissue factor; Tissue factor pathway inhibitor; Tryptophan

Indexed keywords

3 HYDROXYKYNURENINE; KYNURENINE; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; 3-HYDROXYKYNURENINE; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; TRYPTOPHAN;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CONSERVATIVE TREATMENT; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DEGRADATION; AGED; ANALOGS AND DERIVATIVES; BLOOD; CASE CONTROL STUDY; CHRONIC DISEASE; KIDNEY DISEASES; METABOLISM; MIDDLE AGED;

ADULT; AGED; CASE-CONTROL STUDIES; CHRONIC DISEASE; FEMALE; HUMANS; KIDNEY DISEASES; KYNURENINE; LIPOPROTEINS; MALE; MIDDLE AGED; THROMBOPLASTIN; TRYPTOPHAN;

EID: 70349814394     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32832da16d     Document Type: Article

References (31)

1. Menon V, Gul A, Sarnak MJ. Cardiovascular risk factors in chronic kidney disease. Kidney Int 2005; 68:1413-1418.
2. US Renal Data System. USRDS 1998 Annual Data Report. Am J Kidney Dis 1998; 32 (Suppl 1):S69-S80.
3. Foley RN, Parfrey P, Samak MJ. Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis 1998; 32 (Suppl 3): S112-S119. (Pubitemid 28527268)
4. Sagripanti A, Barsotti G. Bleeding and thrombosis in chronic uremia. Nephron 1997; 75:125-139.
5. Kaikita K, Takeya M, Ogawa H, Suefuji H, Yasue H, Takahashi K. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis. J Pathol 1999; 188:180-188. (Pubitemid 29253938)
6. Engelmann B, Luther T, Müller I. Intravascular tissue factor pathway: a model for rapid initiation of coagulation within the blood vessel. Throm Haemost 2003; 89:3-8.
7. Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001; 86:959-972.
8. Mezzano D, Tagle R, Pais E, Panes O, Perez M, Downey P, et al. Endothelial cell markers in chronic uremia: relationship with hemostatic defects and severity of renal failure. Thromb Res 1997; 88:465-472.
9. Kario M, Matsuo T, Matsuo M, Koide M, Yamada T, Nakamura S, et al. Marked increase of activated factor VII in uremic patients. Thromb Haemost 1995; 73:763-767.
10. Cetin O, Bekpinar S, Unlucerci Y, Turkmen A, Bayram C, Ulutin T. Hyperhomocysteinemia in chronic renal failure patients: relation to tissue factor and platelet aggregation. Clin Nephrol 2006; 65:97-102.
11. Al-Saady NM, Leatham EW, Gupta S, Kwan JTC, Eastwood JB, Seymour CA. Monocyte expression of tissue factor and adhesion molecules: the link with accelerated coronary artery disease in patients with chronic renal failure. Heart 1999; 81:134-140.
12. Malyszko J, Malyszko JS, Mysliwiec M. Endothelial cell injury markers in chronic renal failure on conservative treatment and continuous ambulatory peritoneal dialysis. Kidney Blood Press Res 2004; 27:71-77.
13. Schroecksnadel K, Frick B, Winkler C, Fusch D. Crucial role of interferon-g and stimulated macrophages in cardiovascular disease. Curr Vasc Pharmacol 2006; 4:205-213.
14. Stone TW. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 1993; 45:309-379.
15. Saito K, Heyes P. Kynurenine pathway enzymes in brain. Recent advances in tryptophan research. New York: Plenum Press; 1996; pp. 485-492.
16. Wirleitner B, Rudzite V, Neurauter G, Murr C, Kalnins U, Erglis A, et al. Immune activation and degradation of tryptophan in coronary heart disease. Eur J Clin Invest 2003; 33:550-554. (Pubitemid 36783213)
17. Rudzite V, Sileniece G, Liepina D, Dalmane A, Zirne R. Impairment of kynurenine metabolism in cardiovascular disease. Adv Exp Med Biol 1991; 294:663-667.
18. Baldo-Enzi G, Baiocchi MR, Bertazzo A, Costa CV, Allegri G. Tryptophan and atherosclerosis. Adv Exp Med Biol 1996; 398:429-432.
19. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S76-S92.
20. Pawlak D, Tankiewicz A, Mysliwiec P, Buczko W. Tryptophan metabolism via the kynurenine pathway in experimental chronic renal failure. Nephron 2002; 90:328-335.
21. Pawlak D, Tankiewicz A, Buczko W. Kynurenine and its metabolites in the rat with experimental renal insufficiency. J Physiol Pharmacol 2001; 52:755-766.
22. Pawlak D, Pawlak K, Malyszko J, Mysliwiec M, Buczko W. Accumulation of toxic products degradation of kynurenine in hemodialized patients. Int Urol Nephrol 2001; 33:399-404.
23. Pawlak D, Koda M, Wolczynski S, Mysliwiec M, Buczko W. Mechanism of inhibitory effect of 3-hydroxykynurenine on erythropoiesis in patients with renal insufficiency. Adv Exp Med Biol 2003; 527:409-414.
24. Kario K, Matsuo T, Yamada T, Matsuo M. Increased tissue factor pathway inhibitor levels in uremic patients on regular hemodialysis. Thromb Haemost 1994; 71:275-279.
25. Pawlak K, Borawski J, Naumnik B, Myś liwiec M. Relationship between oxidative stress and extrinsic coagulation pathway in haemodialyzed patients. Thromb Res 2003; 109:247-251.
26. Pawlak K, Pawlak D, Mysliwiec M. Association between tissue factor, its pathway inhibitor and oxidative stress in peritoneal dialysis patients. Blood Coagul Fibrinolysis 2007; 18:467-471.
27. Pawlak K, Domaniewski T, Mysliwiec M, Pawlak D. The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease. Atherosclerosis 2008; 204:309-314. doi: 10.1016/ j.atherosclerosis.2008.08.014.
28. Okuda S, Nishiyama N, Saito H, Katsuki H. 3-Hydroxykynurenine, an endogenous oxidative stress generator, caused neuronal cell death with apoptotic features and region selectivity. J Neurochem 1998; 70:299-307.
29. Forrest CM, Mackay GM, Stoy N, Egerton M, Christofides J, et al. Tryptophan loading induces oxidative stress. Free Rad Res 2004; 38:1167-1171.
30. Brisseau GF, Dackiw APB, Cheung PYC, Christie N, Rotstein OD. Posttranscriptional regulation of macrophage tissue factor expression by antioxidants. Blood 1995; 85:1025-1035.
31. Halliwell B. The role of oxygen radicals in human disease, with particular reference to vascular system. Haemostasis 1993; 23 (Suppl 1):118-126.